Preventing leukemia relapse after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with acute myeloid leukemia (AML), a type of blood cancer.
- You had a stem cell transplant from a donor 28–60 days before starting the trial.
- Your bone marrow shows signs that you might relapse, like having some cancer cells left (called minimal residual disease) or other high-risk features.
- You are well enough to be up and about (ECOG score less than 3) and your organs are working well enough.
- You have not had a relapse of your leukemia at the start of the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.